Compass Pathways plc is a clinical-stage biopharmaceutical company focused on developing COMP360, its proprietary formulation of synthetic psilocybin, for treatment-resistant depression (TRD) and other mental health conditions. The company is conducting one of the largest randomized, controlled trials of psilocybin therapy to date, with a Phase 3 program that began in 2021. The question of when Compass will submit a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) is central to the company's future and to the broader field of psychedelic medicine. An NDA is the formal step a drug sponsor takes to request FDA approval to market a new pharmaceutical in the United States. For COMP360, the NDA submission would mark the culmination of years of clinical trials and regulatory interactions, and it would signal that the company believes it has sufficient evidence of safety and efficacy to support commercial use. As of early 2025, Compass Pathways has completed its Phase 3 program for COMP360 in TRD, with top-line results from the first Phase 3 trial (COMP 005) announced in November 2024, and the second trial (COMP 006) results expected in mid-2025. The company has also conducted a long-term follow-up study and a Phase 2 trial in PTSD. The FDA has granted Breakthrough Therapy designation to COMP360 for TRD, which provides for more intensive guidance and a rolling review of the NDA. The company has stated that it plans to submit an NDA in the first half of 2026, pending successful completion of the Phase 3 program and regulatory discussions. However, the exact timing is subject to data quality, manufacturing scale-up, and the FDA's requirements for risk evaluation and mitigation strategies (REMS) due to the psychedelic nature of the drug. The interest in this prediction market stems from the high stakes for patients, investors, and the psychedelic therapy industry. If COMP360 receives FDA approval, it would be the first FDA-approved psilocybin-based therapy, opening a new category of mental health treatment. The market's resolution date of before 2027 creates a clear timeline for the event, and the early close condition means that if the NDA is submitted earlier, the market resolves immediately. This makes the market a real-time indicator of the company's progress and the likelihood of meeting its stated timeline. For those following the space, the NDA submission is a key milestone that would trigger a significant revaluation of Compass's stock and would likely accelerate investment in other psychedelic drug developers. It also carries regulatory implications, as the FDA's handling of a Schedule I substance like psilocybin will set precedents for how other psychedelics (e.g., MDMA, LSD) might be reviewed in the future. The market thus captures not only a corporate event but a transformative moment in psychiatric medicine.

Historical Context

The modern era of psychedelic research began in the 1990s and 2000s with small academic studies, but the field gained traction after 2010 when researchers at Imperial College London and Johns Hopkins University published landmark papers on psilocybin's effects. In 2016, Compass Pathways was founded to develop a pharmaceutical-grade psilocybin, and in 2018 the FDA granted Breakthrough Therapy designation for COMP360 in treatment-resistant depression, a move that signaled regulatory openness to psychedelics. This was a turning point, as it encouraged other companies like MAPS (now Lykos Therapeutics) to pursue FDA approval for MDMA-assisted therapy. Compass's clinical program has progressed through several stages. A Phase 1 trial in healthy volunteers was completed in 2018, followed by a Phase 2b dose-finding study in TRD patients, which reported positive results in 2021. The Phase 3 program, consisting of two trials (COMP 005 and COMP 006), was initiated in 2021. COMP 005, which compared a single 25mg dose of COMP360 with placebo, missed its primary endpoint in a topline readout announced in November 2024, causing a significant drop in Compass's stock price. However, the company noted that the trial showed a signal in a secondary measure (the Montgomery-Åsberg Depression Rating Scale) and that the results were confounded by a high placebo response. COMP 006, which includes multiple doses and a functional unblinding design, is expected to read out in mid-2025. The FDA's requirement for a REMS, which might include healthcare provider training and patient monitoring, is another historical precedent, as it was used for other CNS drugs like clozapine. Historically, NDA submissions for psychiatric drugs have taken from 6 to 12 months after the completion of pivotal trials, depending on the completeness of the data package and the FDA's review priorities. For example, esketamine (Spravato), a ketamine-derived nasal spray for TRD, was submitted as an NDA in 2018 and approved in 2019, about a year after the submission. That precedent is relevant because esketamine also required a REMS and was a novel mechanism for depression. Compass has stated that it will submit the NDA in the first half of 2026, which would be about 12 to 18 months after the completion of the Phase 3 program, assuming COMP 006 is successful and the data are sufficient.